AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
1min snip
GLP-1 Agonists and the Gut Microbiome: Unveiling Their Role in Metabolic Health | Solo Episode
The Dr. Tyna Show
Balance Diversity Over Abundance in Intestinal Flora
GLP1 agonists are effective first-line treatments for type 2 diabetes, facilitating blood glucose regulation by enhancing insulin secretion and reducing glucagon levels. Research indicates that while significant changes in intestinal flora are absent after one week of dulaglutide treatment, noteworthy alterations occur after 48 weeks, marked by a reduced abundance of intestinal flora. An excess of flora, such as seen in small intestinal bacterial overgrowth (SIBO), can be problematic; therefore, a focus on diversity rather than sheer abundance is crucial. Additionally, there is a strong correlation between fasting glucose, C-peptide levels, hemoglobin A1C, BMI, and intestinal flora, suggesting that changes in intestinal flora might play a key role in the therapeutic effects of dulaglutide in managing type 2 diabetes.
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode